Pharma Mar, S.A. (BME:PHM)

Spain · Delayed Price · Currency is EUR

98.65

+1.80 (1.86%)

Apr 28, 2026, 5:35 PM CET

35.60% (1Y)

Market Cap	1.71B
Revenue (ttm)	221.39M
Net Income (ttm)	74.99M
Shares Out	17.36M
EPS (ttm)	4.30
PE Ratio	22.94
Forward PE	37.49
Dividend	0.80 (0.83%)
Ex-Dividend Date	Jun 25, 2025

Volume	67,313
Average Volume	82,696
Open	96.90
Previous Close	96.85
Day's Range	94.85 - 98.95
52-Week Range	70.10 - 102.40
Beta	0.32
RSI	63.86
Earnings Date	Apr 29, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1986

Employees 505

Stock Exchange Madrid Stock Exchange

Ticker Symbol PHM

Full Company Profile

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Financial Statements

News

There is no news available yet.